At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NAMS NEWAMSTERDAM PHARMA CO NV
Pre-Mkt 10-22 08:35:10 EDT
21.49
-0.01
-0.05%
盘前20.00
-1.49-6.93%
08:12 EDT
High22.29Low21.31Vol1.25M
Open21.58D1 Closing21.50Amplitude4.56%
Mkt Cap2.57BTradable Cap1.95BTotal Shares119.54M
T/O27.17MT/O Rate1.38%Tradable Shares90.76M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

NewAmsterdam PREVAIL Interim Faces 'Considerable' Risk, RBC Says
MT Newswires Live  ·  10-05
NewAmsterdam PREVAIL Interim Faces 'Considerable' Risk, RBC Says
RBC Cuts Price Target on NewAmsterdam Pharma to $42 From $50, Keeps Outperform, Speculative Risk
MT Newswires Live  ·  10-05
RBC Cuts Price Target on NewAmsterdam Pharma to $42 From $50, Keeps Outperform, Speculative Risk
13D Filings
Dow Jones  ·  10-03
13D Filings
NewAmsterdam Pharma CSO Johannes Jacob Pieter Kastelein Reports $1,257,659 Share Disposal
Reuters  ·  10-03
NewAmsterdam Pharma CSO Johannes Jacob Pieter Kastelein Reports $1,257,659 Share Disposal
NewAmsterdam Pharma Grants 71,800 Inducement Stock Options to New Hires at USD 24.16 Per Share
Reuters  ·  10-03
NewAmsterdam Pharma Grants 71,800 Inducement Stock Options to New Hires at USD 24.16 Per Share
Analysts Are Bullish on Top Healthcare Stocks: Invivyd (IVVD), NewAmsterdam Pharma Company (NAMS)
TIPRANKS  ·  09-30
Analysts Are Bullish on Top Healthcare Stocks: Invivyd (IVVD), NewAmsterdam Pharma Company (NAMS)
NewAmsterdam Pharma Doses First Patient in Phase 2b Spinoza Trial of Obicetrapib in Preclinical Alzheimer’s Disease
Reuters  ·  09-29
NewAmsterdam Pharma Doses First Patient in Phase 2b Spinoza Trial of Obicetrapib in Preclinical Alzheimer’s Disease
Menarini Group & Newamsterdam Pharma Receive European Commission Approval for Ubeslo and Evlarco
Reuters  ·  09-22
Menarini Group & Newamsterdam Pharma Receive European Commission Approval for Ubeslo and Evlarco
Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Lipocine (LPCN)
TIPRANKS  ·  09-22
Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Lipocine (LPCN)
NewAmsterdam Pharma Gets EU Approval for Ubeslo, Evlarco
MT Newswires Live  ·  09-21
NewAmsterdam Pharma Gets EU Approval for Ubeslo, Evlarco
NewAmsterdam Pharma Price Target Maintained with a $52.00/Share by HC Wainwright & Co.
Dow Jones  ·  09-08
NewAmsterdam Pharma Price Target Maintained with a $52.00/Share by HC Wainwright & Co.
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), NewAmsterdam Pharma Company (NAMS) and Ionis Pharmaceuticals (IONS)
TIPRANKS  ·  09-08
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), NewAmsterdam Pharma Company (NAMS) and Ionis Pharmaceuticals (IONS)
Why the Dow is Being Dragged Down by a Swiss Company's Bad News
Dow Jones  ·  09-08
Why the Dow is Being Dragged Down by a Swiss Company's Bad News
Novartis Cholesterol Setback Tests Hopes for Emerging Heart Disease Drugs
Reuters  ·  09-07
Novartis Cholesterol Setback Tests Hopes for Emerging Heart Disease Drugs
Newamsterdam Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Reuters  ·  09-04
Newamsterdam Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NewAmsterdam Pharma Grants Inducement Share Options for 52,900 Shares at $24.92 Each
Reuters  ·  09-04
NewAmsterdam Pharma Grants Inducement Share Options for 52,900 Shares at $24.92 Each
NewAmsterdam Pharma to Present Phase 3 Obicetrapib Trial Data at ESC Congress 2026
Reuters  ·  08-26
NewAmsterdam Pharma to Present Phase 3 Obicetrapib Trial Data at ESC Congress 2026
NewAmsterdam Pharma CSO Johannes Kastelein Disposes of 125,000 Shares for USD 3.36 Million
Reuters  ·  08-26
NewAmsterdam Pharma CSO Johannes Kastelein Disposes of 125,000 Shares for USD 3.36 Million
NewAmsterdam Pharma Amends 8-K to Disclose COO Douglas Kling Separation, Advisor Agreement Terms
Reuters  ·  08-15
NewAmsterdam Pharma Amends 8-K to Disclose COO Douglas Kling Separation, Advisor Agreement Terms
NewAmsterdam Pharma Appoints Robert Gunning Principal Accounting Officer
Reuters  ·  08-15
NewAmsterdam Pharma Appoints Robert Gunning Principal Accounting Officer

Introduction

Company Name.
NEWAMSTERDAM PHARMA CO NV
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Issue price:
--